Evaluation of bone remodeling in hemodialysis patients: Serum biochemistry, circulating cytokines and bone histomorphometry

Journal of Nephrology

Volumn 22, Issue 6, 2009, Pages 783-793

  Ferreira, Anibal ^a   Saraiva, Maria ^a   Behets, Geert ^b   Macedo, Ana ^c   Galvão, Maria ^a   D'Haese, Patrick ^b   Drüeke, Tilman B ^d  

^a HOSPITAL CURRY CABRAL   (Portugal)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c KeyPoint   (Portugal)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Bone biopsy; Cytokines; Histomorphometry; Intact parathyroid hormone; Renal Osteodystrophy; Total alkaline phosphatases

Indexed keywords

ALKALINE PHOSPHATASE; ALUMINUM; CALCIUM; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PARATHYROID HORMONE; PHOSPHATE; SOLUBLE INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ALUMINUM BLOOD LEVEL; ARTICLE; BONE BIOPSY; BONE DISEASE; BONE REMODELING; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; ILIAC BONE; IMMUNOASSAY; MALE; MORPHOMETRICS; OSSIFICATION; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PREDICTION; SENSITIVITY AND SPECIFICITY;

ADULT; ALKALINE PHOSPHATASE; ALUMINUM; BIOLOGICAL MARKERS; BIOPSY; BONE REMODELING; CALCIUM; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; ILIUM; INTERLEUKINS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 72149108705     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Moe SM, Drueke T, Cunningham J, et al. Definition, evaluation and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945-1953.
2. Coen G, Mazzaferro S, Ballanti P, et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross sectional study. Nephrol Dial Transplant. 1996;11:813-819.
3. Martin KJ, Olgaard K, Coburn JW, et al. Diagnosis, assessment and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004;43:558-565.
4. Ferreira A. Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when one biopsy is needed. Nephrol Dial Transplant. 2000;15:8-14.
5. Ho LT, Sprague S. Percutaneous bone biopsy in the diagnosis of renal osteodystrophy. Semin Nephrol. 2002;22:268-275.
6. Ferreira A, Drüeke TB. How to diagnose the different forms of renal osteodystrophy: role of biochemical markers. Am J Med Sci. 2000;320:85-89.
7. David V, Lafage-Proust MH, Laroche N, Christian A, Ruegsegger P, Vico L. Two-week longitudinal survey of bone architecture alteration in the hindlimb-unloaded rat model of bone loss: sex differences. Am J Physiol Endocrinol Metab. 2006;290:440-447.
8. Qi Q, Maunier-Faugere MC, Geng Z, Malluche H. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995;22:622-631.
9. Cohen-Solal ME, Sebert JL, Boudailliez B, et al. Comparison of intact, midregion and carboy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab. 1991;71:516-524.
10. Barreto FC, Barreto DV, Moysés RMA, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008;73:771-777.
11. Lepage R, Ray L, Bossard J-H, et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem. 1998;44:805-809.
12. Malluche H, Mawad H, Trueba D, Monier-Faugere M-C. Parathyroid hormone assays: evolution and revolutions in the care of dialysis patients. Clin Nephrol. 2003;59:313-318.
13. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D'Amour P. Synthetic carboxy-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from PTH/PTH related peptide receptor. Endocrinology. 2001;142:1386-1392.
14. Coen G, Ballanti P, Bonnuci E, et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant. 1998;13:2294-2302.
15. Goodman WG, Salusky IB, Jüpner H. New lessons from old assays (PTH), its receptors, and the potential biological relevance of PTH fragments. Nephrol Dial Transplant. 2002;17:1731-1736.
16. Ureña P, de Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int. 1999;55:2141-2156.
17. Ureña P, Ferreira A, Kung V, et al. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res. 1995;10:932-939.
18. Bervoets AR, Spasovski GB, Behets GJ, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003;41:997-1007.
19. Ureña P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol. 1996;7:1-7.
20. Couttenye MM, D'Haese PC, Van Hoof VO, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant. 1996;11:1065-1072.
21. Ferreira A, Simon P, Drueke T, Descamps-Latscha B. Potential role of cytokines in renal osteodystrophy. Nephrol Dial Transplant. 1996;11:399-400.
22. Duarte ME, Carvalho EF, Cruz EA, Lucena SB, Andress DL. Cytokine accumulation in osteitis fibrosa of renal osteodystrophy. Braz J Med Biol Res. 2002;35:25-29.
23. Herbelin A, Nguyen AT, Zingraff J, Ureña P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int. 1990;37:116-125.
24. Herbelin A, Ureña P, Nguyen AT. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int. 1991;39:954-960.
25. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res. 1987;6:595-610.
26. Salusky IB, Coburn JW, Brill J, et al. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int. 1988;:38975-38982.
27. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:2591-2592.
28. Ferreira A. Development of renal bone disease. Eur J Clin Invest. 2006;36:2-12.
29. Ferreira A, Frazão JM, Monier-Faugere M-C, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008;19:405-412.
30. Boyle WB, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342.
31. Hruska KA, Teitelbaum SL. Mechanisms of disease: renal osteodystrophy. N Engl J Med. 1995;333:166-174.
32. Jung Y, Wang J, Schneider A, et al. Regulation of SDF-1 (CXCL12) production by osteoblasts: a possible mechanism for stem cell homing. Bone. 2006;38:497-508.
33. Hruska KA. New concepts in renal osteodystrophy. Nephrol Dial Transplant. 1998;13:2755-2760.
34. Koh AJ, Demiralp B, Neiva KG, et al. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology. 2005;146:4584-4596.
35. Ferreira A, Ghazali A, Galvao J, et al. Effect of type of dialysis membrane on bone in haemodialysis patients. Nephrol Dial Transplant. 2001;16:1230-1238.
36. Steddon SJ, McIntyre CW, Schroeder NJ, Burrin JM, Cunningham J. Impaired release of interleukin-6 from human osteoblastic cells in the uremic milieu. Nephrol Dial Transplant. 2004;19:3078-3083.
37. Barreto FC, Barreto DV, Moyses RM, et al. Osteoporosis in hemodialysis patients revisited by bone histomor phometry: a new insight into an old problem. Kidney Int. 2006;69:1852-1857.
38. Descamps-Latscha B, Herbelin A, Nguyen AT, et al. Balance between IL-1 beta, TNF alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis: relationships with activation markers of T cells, B cells and monocytes. J Immunol. 1995;154:882-892.
39. Montalban C, Garcia-Unzueta MT, De Francisco A, Amado JA. Serum interleukin-6 in renal osteodystrophy: relationship with serum PTH and bone remodeling markers. Horm Metab Res. 1999;31:14-17.
40. Santos FR, Moyses RM, Montenegro FL, Jorgetti V, Noronha IL. IL-1beta, TNF-alpha, TGF-beta and BFGF expression in bone biopsies before and after parathyroidectomy. Kidney Int. 2003;63:899-907.
41. Liu XH, Kirschenbaum A, Yao S, Levine AC. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/ receptor activator of nuclear factor-kB (RANK) ligand/RANK system. Endocrinology. 2005;146:1991-1998.
42. Kudo O, Sabokbar A, Pocock A, et al. Interleukin-6 and interleukin 11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32:1-7.
43. Ernest HS, Choy MD, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-916.
44. Jacobsen SE, Veyby OP, Smelan EB. Cytotoxic lymphocyte maturation factor (interleukin 12) is a synergistic growth factor for hematopoietic stem cells. J Exp Med. 1993;178:413-418.
45. Kollet O. Ayelet Dar, Lapidot T. The multiple roles of osteoclast in host defense: bone remodeling and hematopoietic stem cell mobilization. Annu Rev Immunol. 2007;25:51-69.